HQL News and Press, TeklaLife Sciences Investors From 12/09/18

The Weekly Closed-End Fund Roundup will be put out at the start of each week to summarize recent price movements in closed-end fund [CEF] sectors in the last week, as well as to highlight recently concluded or upcoming corporate actions on CEFs, such as tender offers. Most of the information...

Yesterday afternoon, I was watching a documentary discussing some of the recent advances in the fields of genetics and biotechnology. While some of the predictions seemed rather far-fetched (like being able to revitalize cells and effectively grant immortality by 2045), it still got me thinkin...

By Ethan Lovell Portfolio Manager Ethan Lovell discusses a new proposal to overhaul drug pricing in Medicare Part B and what it could mean for drug manufacturers. Key Takeaways A proposal to lower drug costs would align Medicare Part B drug prices with prices outside the U.S., wher...

We've turned the page to November, and investors across the globe may feel a bit of unconscious relief. Stock markets do fluctuate, but months like October are never fun. And that has been especially acute in biotech. Leading ETFs like IBB and XBI dropped ~15% and 18% respectively in October...

On October 31, 2018, Tekla Healthcare Opportunities Fund paid a monthly distribution of $0.1125 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains, net realized long-term capital gains and return of capital or other capital sourc...

On October 31, 2018, Tekla World Healthcare Fund paid a monthly distribution of $0.1167 per share. It is currently estimated that this distribution is derived from return of capital or other capital source. The composition of this and subsequent distributions may vary from month to month bec...

Speaking at the Department of Health & Human Services, the president says both consumers and the government can save money if drugs were priced along the lines of that of other countries (i.e., Canada). More news on: iShares Nasdaq Biotechnology ETF, Health Care Select Sect SPDR ETF,...

On September 28, 2018, Tekla Life Sciences Investors paid a distribution of $0.40 per share. It is currently estimated that this distribution is derived from net realized short-term capital gains and return of capital or other capital source. The composition of this and subsequent distributi...

On September 28, 2018, Tekla Healthcare Investors paid a distribution of $0.47 per share. It is currently estimated that this distribution is derived from net realized long-term capital gains. The composition of this and subsequent distributions may vary from quarter to quarter because it ma...

By Evan McCulloch, Senior Vice President, Director of Research Franklin Equity Group ® Portfolio Manager, Franklin Biotechnology Discovery Fund Franklin Equity Group's Evan McCulloch explains why higher rates of drug utilization and healthcare spending are lending support to the b...